Ivabradine 7.5
Small molecule
Ivabradine 7.5 is one of 40 small molecule programs targeting Coronary Artery Disease. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
223 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Leqvio
NovartisPhase 3
Byetta
AstraZenecaPhase 3
Zetia
OOrganon and Co
Phase 3
Xe-133
NNobilis Therapeutics Inc.
Phase 3
Ridaforolimus
Merck & Co.Phase 3
Glutamine
SanofiPhase 3
Quercetin
MMayo Clinic
Phase 3
Praluent
RegeneronPreclinical
Repatha
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ivabradine 7.5. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- GGødstrup Hospital